PDF下载 ( 1971 KB)
超声引导下肝癌热消融治疗的现状与进展
DOI: 10.3969/j.issn.1001-5256.2021.03.004
利益冲突声明: 所有作者均声明不存在利益冲突。
作者贡献声明：李鑫负责文献检索，撰写修改论文；梁萍负责拟定写作思路及最后定稿。
Current status and advances in ultrasound-guided thermal ablation for hepatocellular carcinoma
-
摘要: 肝癌是临床上常见的恶性肿瘤，影像引导下热消融治疗为早期肝癌根治性治疗手段，为中晚期肝癌的姑息减瘤及联合系统治疗的主要手段之一。超声技术以其显像实时、引导准确、操作简便、移动便捷、费用低廉、无辐射损伤及高效节能等优势在肝癌热消融治疗术前规划、术中引导、术后评估及长期随访中发挥重要作用，尤其随着超声与影像融合技术的进步以及与光声成像为代表的功能影像技术的发展，使超声引导下热消融走在肝癌精准治疗的最前沿，并保持持久发展，向更微创、精准、安全、有效的诊疗模式发展。Abstract: Hepatocellular carcinoma (HCC) is a common malignant tumor in clinical practice, and image-guided thermal ablation is a radical treatment method for early-stage HCC and a method for palliative tumor reduction and combination with systematic therapy for advanced HCC. With the advantages of real-time imaging, accurate guiding, easy operation, portability, low cost, no radiation damage, and high efficiency, ultrasound plays an important role in preoperative planning, intraoperative guiding, postoperative evaluation, and long-term follow-up in thermal ablation for HCC. With the advances in ultrasound and imaging fusion technology and the development of functional imaging technology represented by photoacoustic imaging, ultrasound-guided thermal ablation is at the forefront of precision treatment of HCC, achieving long-lasting development and developing into a more minimally invasive, accurate, safe, and effective diagnostic and therapeutic mode.
-
[1] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380: 1450-1462. DOI: 10.1056/NEJMra1713263 [2] ZHOU M, WANG H, ZENG X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. DOI: 10.1016/S0140-6736(19)30427-1 [3] XIE DY, REN ZG, ZHOU J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: Updates and insights[J]. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463. DOI: 10.21037/hbsn-20-480 [4] Global Burden of Disease Liver Cancer Collaboration, AKINYEMIJU T, ABERA S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691. DOI: 10.1001/jamaoncol.2017.3055 [5] LIANG P, YU J, YU XL, et al. Percutaneous cooled-tip microwave ablation under ultrasound guidance for primary liver cancer: A multicentre analysis of 1363 treatment-naive lesions in 1007 patients in China[J]. Gut, 2012, 61(7): 1100-1101. DOI: 10.1136/gutjnl-2011-300975 [6] CHEN Z, XIE H, HU M, et al. Recent progress in treatment of hepatocellular carcinoma[J]. Am J Cancer Res, 2020, 10(9): 2993-3036. http://www.researchgate.net/publication/346262415_Recent_progress_in_treatment_of_hepatocellular_carcinoma [7] LIANG P, DONG B, YU X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation[J]. Radiology, 2005, 235(1): 299-307. DOI: 10.1148/radiol.2351031944 [8] YU J, YU XL, HAN ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: A phase Ⅲ randomised controlled trial[J]. Gut, 2017, 66(6): 1172-1173. DOI: 10.1136/gutjnl-2016-312629 [9] LIU W, ZHENG Y, HE W, et al. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: A propensity score analysis[J]. Aliment Pharmacol Ther, 2018, 48(6): 671-681. DOI: 10.1111/apt.14929 [10] ROSSI S, FORNARI F, BUSCARINI L. Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma[J]. J Intervent Radiol, 1993, 8: 97-103. http://ci.nii.ac.jp/naid/10005251016 [11] SEKI T, WAKABAYASHI M, NAKAGAWA T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma[J]. Cancer, 1994, 74(3): 817-825. DOI: 10.1002/1097-0142(19940801)74:3<817::AID-CNCR2820740306>3.0.CO;2-8 [12] TSUKAMOTO M, YAMASHITA YI, IMAI K, et al. Long-term favorable outcomes of radiofrequency ablation for hepatocellular carcinoma as an initial treatment: A single-center experience over a 10-year period[J]. Anticancer Res, 2018, 38(2): 1047-1052. http://www.ncbi.nlm.nih.gov/pubmed/29374739 [13] LIANG P, YU J, LU MD, et al. Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy[J]. World J Gastroenterol, 2013, 19(33): 5430-5438. DOI: 10.3748/wjg.v19.i33.5430 [14] LORENTZEN T, NOLSOE CP, EWERTSEN C, et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part I. General Aspects (Short Version)[J]. Ultraschall Med, 2015, 36(5): 464-472. DOI: 10.1055/s-0035-1553601 [15] LORENTZEN T, NOLSOE CP, EWERTSEN C, et al. EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part I. General Aspects (long Version)[J]. Ultraschall Med, 2015, 36(5): e1-e14. DOI: 10.1055/s-0035-1553593.pdf [16] NOLSØE CP, NOLSØE AB, KLUBIEN J, et al. Use of ultrasound contrast agents in relation to percutaneous interventional procedures: A systematic review and pictorial essay[J]. J Ultrasound Med, 2018, 37(6): 1305-1324. DOI: 10.1002/jum.14498 [17] LIU F, YU X, LIANG P, et al. Contrast-enhanced ultrasound-guided microwave ablation for hepatocellular carcinoma inconspicuous on conventional ultrasound[J]. Int J Hyperthermia, 2011, 27(6): 555-562. DOI: 10.3109/02656736.2011.564262 [18] CHAN AK, HEGARTY C, KLASS D, et al. The role of contrast-enhanced ultrasound in guiding radiofrequency ablation of hepatocellular carcinoma: A retrospective study[J]. Can Assoc Radiol J, 2015, 66(2): 171-178. DOI: 10.1016/j.carj.2014.11.005 [19] PARK HS, KIM YJ, YU MH, et al. Real-time contrast-enhanced sonographically guided biopsy or radiofrequency ablation of focal liver lesions using perflurobutane microbubbles (sonazoid): Value of Kupffer-phase imaging[J]. J Ultrasound Med, 2015, 34(3): 411-421. DOI: 10.7863/ultra.34.3.411 [20] FRANCICA G, MELONI MF, DE SIO I, et al. Biopsy of liver target lesions under contrast-enhanced ultrasound guidance - A multi-center study[J]. Ultraschall Med, 2018, 39(4): 448-453. DOI: 10.1055/s-0043-122496 [21] FRANCICA G, MELONI MF, RICCARDI L, et al. Ablation treatment of primary and secondary liver tumors under contrast-enhanced ultrasound guidance in field practice of interventional ultrasound centers. A multicenter study[J]. Eur J Radiol, 2018, 105: 96-101. DOI: 10.1016/j.ejrad.2018.05.030 [22] MASUZAKI R, SHⅡNA S, TATEISHI R, et al. Utility of contrast-enhanced ultrasonography with Sonazoid in radiofrequency ablation for hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2011, 26(4): 759-764. DOI: 10.1111/j.1440-1746.2010.06559.x [23] DIETRICH CF, NOLSOE CP, BARR RG, et al. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS[J]. Ultrasound Med Biol, 2020, 46(10): 2579-2604. DOI: 10.1016/j.ultrasmedbio.2020.04.030 [24] LI X, XU M, LIU M, et al. Contrast-enhanced ultrasound-guided feeding artery ablation as add-on to percutaneous radiofrequency ablation for hypervascular hepatocellular carcinoma with a modified ablative technique and tumor perfusion evaluation[J]. Int J Hyperthermia, 2020, 37(1): 1016-1026. DOI: 10.1080/02656736.2020.1811902 [25] MAURI G, PORAZZI E, COVA L, et al. Intraprocedural contrast-enhanced ultrasound (CEUS) in liver percutaneous radiofrequency ablation: Clinical impact and health technology assessment[J]. Insights Imaging, 2014, 5(2): 209-216. DOI: 10.1007/s13244-014-0315-7 [26] XU E, LONG Y, LI K, et al. Comparison of CT/MRI-CEUS and US-CEUS fusion imaging techniques in the assessment of the thermal ablation of liver tumors[J]. Int J Hyperthermia, 2019, 35(1): 159-167. http://www.ncbi.nlm.nih.gov/pubmed/30300032 [27] MINAMI Y, NISHIDA N, KUDO M. Therapeutic response assessment of RFA for HCC: Contrast-enhanced US, CT and MRI[J]. World J Gastroenterol, 2014, 20(15): 4160-4166. DOI: 10.3748/wjg.v20.i15.4160 [28] MELONI MF, FRANCICA G, CHIANG J, et al. Use of contrast-enhanced ultrasound in ablation therapy of HCC: Planning, guiding, and assessing treatment response[J]. J Ultrasound Med, 2020.[Online ahead of print] [29] TOWNSEND DW, WENSVEEN M, BYARS LG, et al. A rotating PET scanner using BGO block detectors: Design, performance and applications[J]. J Nucl Med, 1993, 34(8): 1367-1376. http://www.ncbi.nlm.nih.gov/pubmed/8326401 [30] RHIM H, LEE MH, KIM YS, et al. Planning sonography to assess the feasibility of percutaneous radiofrequency ablation of hepatocellular carcinomas[J]. AJR Am J Roentgenol, 2008, 190(5): 1324-1330. DOI: 10.2214/AJR.07.2970 [31] LEE MW, LIM HK, KIM YJ, et al. Percutaneous sonographically guided radio frequency ablation of hepatocellular carcinoma: Causes of mistargeting and factors affecting the feasibility of a second ablation session[J]. J Ultrasound Med, 2011, 30(5): 607-615. DOI: 10.7863/jum.2011.30.5.607 [32] LIU FY, YU XL, LIANG P, et al. Microwave ablation assisted by a real-time virtual navigation system for hepatocellular carcinoma undetectable by conventional ultrasonography[J]. Eur J Radiol, 2012, 81(7): 1455-1459. DOI: 10.1016/j.ejrad.2011.03.057 [33] SONG KD, LEE MW, RHIM H, et al. Percutaneous US/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: Technical feasibility and therapeutic outcomes[J]. Radiology, 2018, 288(3): 878-886. DOI: 10.1148/radiol.2018172743 [34] IYER RS, TIMM BA, MITSUMORI LM, et al. Image fusion as a new postprocessing method to evaluate the radiofrequency ablation zone after treatment of malignant liver tumors[J]. J Comput Assist Tomogr, 2010, 34(2): 226-228. DOI: 10.1097/RCT.0b013e3181c4f797 [35] NUMATA K, FUKUDA H, MORIMOTO M, et al. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma[J]. Eur J Radiol, 2012, 81(10): 2746-2753. DOI: 10.1016/j.ejrad.2011.11.052 [36] ZHONG-ZHEN S, KAI L, RONG-QIN Z, et al. A feasibility study for determining ablative margin with 3D-CEUS-CT/MR image fusion after radiofrequency ablation of hepatocellular carcinoma[J]. Ultraschall Med, 2012, 33(7): e250-e255. DOI: 10.1055/s-0032-1325466 [37] CHENG Q, QIAN ML. Progresses of multi-modality photoacoustic molecular imaging[J]. Appl Acoust, 2018, 37(5): 645-654. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YYSN201805008.htm程茜, 钱梦騄. 多模态光声分子成像进展[J]. 应用声学, 2018, 37(5): 645-654. https://www.cnki.com.cn/Article/CJFDTOTAL-YYSN201805008.htm [38] ZHANG XJ, WANG QD, LIAN YZ. Albumin-based SPECT/photoacoustic dual-modality nanoprobe in liver imaging[J]. Chin J Med Imaging, 2017, 25(10): 729-733. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYZ201710004.htm张晓洁, 王庆大, 连云宗. SPECT/光声双模态纳米探针在肝成像中的应用[J]. 中国医学影像学杂志, 2017, 25(10): 729-733. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYZ201710004.htm [39] ZHOU Q, LI Z, ZHOU J, et al. In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft[J]. Photoacoustics, 2016, 4(2): 43-54. DOI: 10.1016/j.pacs.2016.04.001 [40] GUAN TP. The synthesis of photoacoustic-flurescence dual modality imaging probe based on Au nanorods and application in liver cancer[D]. Guangzhou: Southern Medical University, 2017. (in Chinese)关天培. 基于金纳米棒的光声-荧光双模分子探针的制备及其在肝癌中的应用[D]. 广州: 南方医科大学, 2017. [41] LI Q, CHEN K, HUANG W, et al. Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma[J]. Cancer Lett, 2021, 496: 169-178. DOI: 10.1016/j.canlet.2020.09.024 -
本文二维码
计量
- 文章访问数: 854
- HTML全文浏览量: 207
- PDF下载量: 102
- 被引次数: 0
下载:
